LT3350180T - 8-[6-[3-(amino)propoksi]-3-piridil]-1-iizopropil-imidazo[4,5-c]chinolin-2-ono dariniai, kaip selektyvūs ataksijos-telangiektazijos mutuotos (atm) kinazės moduliatoriai, skirti vėžio gydymui - Google Patents

8-[6-[3-(amino)propoksi]-3-piridil]-1-iizopropil-imidazo[4,5-c]chinolin-2-ono dariniai, kaip selektyvūs ataksijos-telangiektazijos mutuotos (atm) kinazės moduliatoriai, skirti vėžio gydymui

Info

Publication number: LT3350180T
Authority: LT; Lithuania
Prior art keywords: telangiectase; mutaed; atacio; imidase; iisopropyl
Prior art date: 2015-09-17

Application number

LTEP16770461.8T

Other languages

English (en)

Inventor

Kurt Pike

Bernard Barlaam

Thomas Hunt

Andrew Eatherton

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-17

Filing date

2016-09-15

Publication date

2021-02-25

2016-09-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2021-02-25 Publication of LT3350180T publication Critical patent/LT3350180T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTEP16770461.8T 2015-09-17 2016-09-15 8-[6-[3-(amino)propoksi]-3-piridil]-1-iizopropil-imidazo[4,5-c]chinolin-2-ono dariniai, kaip selektyvūs ataksijos-telangiektazijos mutuotos (atm) kinazės moduliatoriai, skirti vėžio gydymui LT3350180T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1516504.6A GB201516504D0 (en)	2015-09-17	2015-09-17	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
PCT/EP2016/071782 WO2017046216A1 (en)	2015-09-17	2016-09-15	8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Publications (1)

Publication Number	Publication Date
LT3350180T true LT3350180T (lt)	2021-02-25

Family

ID=54544418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP16770461.8T LT3350180T (lt)	2015-09-17	2016-09-15	8-[6-[3-(amino)propoksi]-3-piridil]-1-iizopropil-imidazo[4,5-c]chinolin-2-ono dariniai, kaip selektyvūs ataksijos-telangiektazijos mutuotos (atm) kinazės moduliatoriai, skirti vėžio gydymui

Country Status (37)

Country	Link
US (5)	US9856255B2 (lt)
EP (2)	EP3683220B1 (lt)
JP (1)	JP6605130B2 (lt)
KR (2)	KR102469153B1 (lt)
CN (1)	CN108137576B (lt)
AR (1)	AR106053A1 (lt)
AU (1)	AU2016323399B2 (lt)
BR (1)	BR112018004325B1 (lt)
CA (1)	CA2997399C (lt)
CL (1)	CL2018000677A1 (lt)
CO (1)	CO2018002829A2 (lt)
CR (1)	CR20180172A (lt)
CY (1)	CY1124680T1 (lt)
DK (2)	DK3683220T3 (lt)
DO (1)	DOP2018000065A (lt)
EA (1)	EA033284B1 (lt)
ES (2)	ES2920876T3 (lt)
GB (1)	GB201516504D0 (lt)
HR (1)	HRP20210149T1 (lt)
HU (2)	HUE058884T2 (lt)
IL (1)	IL257847B (lt)
LT (1)	LT3350180T (lt)
MX (1)	MX384930B (lt)
MY (2)	MY198813A (lt)
NI (1)	NI201800033A (lt)
PE (1)	PE20181078A1 (lt)
PH (1)	PH12018500532A1 (lt)
PL (2)	PL3350180T3 (lt)
PT (2)	PT3350180T (lt)
RS (1)	RS61435B1 (lt)
SI (1)	SI3350180T1 (lt)
SM (1)	SMT202100071T1 (lt)
SV (1)	SV2018005655A (lt)
TN (1)	TN2018000078A1 (lt)
TW (2)	TWI762109B (lt)
WO (1)	WO2017046216A1 (lt)
ZA (1)	ZA202209171B (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201516504D0 (en) *	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) *	2016-05-11	2016-06-22	Astrazeneca Ab	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JOP20190209A1 (ar) *	2017-03-16	2019-09-12	Astrazeneca Ab	مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh)	2017-09-20	2020-06-26	阿斯利康(瑞典)有限公司	1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
ES3001444T3 (en) *	2018-09-14	2025-03-05	Suzhou Zanrong Pharma Ltd	1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115003672A (zh) *	2020-01-09	2022-09-02	南京明德新药研发有限公司	喹啉并咪唑类化合物及其应用
US20230293507A1 (en) *	2020-03-04	2023-09-21	Pharos Ibio Co., Ltd	Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer
JP2023539715A (ja) *	2020-06-24	2023-09-19	アストラゼネカユーケーリミテッド	抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
CN119954827A (zh) *	2020-09-28	2025-05-09	石药集团中奇制药技术（石家庄）有限公司	一类并环化合物及其制备和应用
EP3992191A1 (en)	2020-11-03	2022-05-04	Deutsches Krebsforschungszentrum	Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022125614A1 (en) *	2020-12-09	2022-06-16	Stingray Therapeutics, Inc.	Phosphonates as inhibitors of enpp1 and cdnp
AU2021433713A1 (en) *	2021-03-17	2023-09-28	Suzhou Zanrong Pharma Limited	Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115304598B (zh) *	2021-08-25	2024-05-31	石药集团中奇制药技术（石家庄）有限公司	一种杂环类化合物及其制备方法和用途
GB202114704D0 (en)	2021-10-14	2021-12-01	Univ Birmingham	ATM inhibition
MX2024009184A (es) *	2022-01-26	2024-07-30	Chia Tai Tianqing Pharmaceutical Group Co Ltd	Compuesto que contiene grupo hidrazino.
AU2022452885A1 (en) *	2022-04-11	2024-09-05	Wei Zhong	Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application
CN121038817A (zh)	2023-04-10	2025-11-28	第一三共株式会社	抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合
WO2025056741A1 (en)	2023-09-13	2025-03-20	Astrazeneca Ab	Azd1390, or a pharmaceutically acceptable salt thereof, in combination with radiation for use in a method of treatment of a cns tumour
TW202535383A (zh)	2024-03-13	2025-09-16	瑞典商阿斯特捷利康公司	治療方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ240313A (en)	1990-10-22	1994-04-27	Res Corp Technologies Inc	Anti-retrovirus compositions containing aryl and heteroaryl derivatives
TW301607B (lt)	1993-03-09	1997-04-01	Takeda Pharm Industry Co Ltd
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CA2242425C (en)	1996-02-13	2006-07-18	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de)	1996-03-05	2002-08-14	Astrazeneca Ab, Soedertaelje	4-anilinochinazolin derivate
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6632823B1 (en)	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
JP2002522388A (ja)	1998-08-03	2002-07-23	ビーエーエスエフコーポレーション	性機能障害の治療のためのピリジノン
WO2000046203A2 (en)	1999-02-04	2000-08-10	Millennium Pharmaceuticals, Inc.	G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US20020151712A1 (en)	1999-09-14	2002-10-17	Nan-Horng Lin	3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
EP1578341A2 (en)	2000-10-11	2005-09-28	Tularik Inc.	Modulation of ccr4 function
WO2002030357A2 (en)	2000-10-11	2002-04-18	Chemocentryx, Inc.	Compounds and methods for modulating ccr4 function
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
WO2002076177A2 (en)	2001-03-23	2002-10-03	Bethesda Pharmaceuticals, Inc.	Design and synthesis of optimized ligands for ppar
JP2002293745A (ja)	2001-03-29	2002-10-09	St Marianna Univ School Of Medicine	慢性関節リウマチ治療剤
CA2442654A1 (en)	2001-04-10	2002-10-10	Transtech Pharma, Inc.	Probes, systems, and methods for drug discovery
US20040116330A1 (en)	2001-04-27	2004-06-17	Kenichiro Naito	Preventive/therapeutic method for cancer
US7144903B2 (en)	2001-05-23	2006-12-05	Amgen Inc.	CCR4 antagonists
EP1270535A3 (de)	2001-06-20	2004-02-18	Clariant GmbH	Verfahren zur Herstellung von substituierten aromatischen Verbindungen
JP4082888B2 (ja)	2001-10-17	2008-04-30	広栄化学工業株式会社	ビアリール化合物の製造法
EP1513522A2 (en)	2002-01-18	2005-03-16	Sri International	Methods of treating conditions associated with an edg receptor
JP4167848B2 (ja)	2002-04-10	2008-10-22	広栄化学工業株式会社	ビアリール化合物の製造法
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
EP1541563A4 (en)	2002-07-10	2007-11-07	Ono Pharmaceutical Co	ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
CA2495903A1 (en)	2002-08-23	2004-03-04	University Of Connecticut	Novel biphenyl and biphenyl-like cannabinoids
US7183313B2 (en)	2002-08-23	2007-02-27	University Of Connecticut	Keto cannabinoids with therapeutic indications
WO2004078756A2 (en)	2003-03-06	2004-09-16	Eisai Co., Ltd.	Jnk inhibitors
JPWO2004080943A1 (ja)	2003-03-11	2006-06-08	小野薬品工業株式会社	シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
WO2004113258A1 (ja)	2003-06-20	2004-12-29	Shionogi & Co., Ltd.	炭素−炭素結合生成反応
EP1661889A4 (en)	2003-09-05	2009-08-05	Ono Pharmaceutical Co	ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
JP2005170939A (ja)	2003-11-20	2005-06-30	Takeda Chem Ind Ltd	糖尿病の予防・治療剤
BRPI0416801A (pt)	2003-11-21	2007-01-09	Novartis Ag	derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
WO2006038594A1 (ja)	2004-10-04	2006-04-13	Ono Pharmaceutical Co., Ltd.	Ｎ型カルシウムチャネル阻害薬
EP2371811B1 (en)	2004-12-13	2014-10-08	Ono Pharmaceutical Co., Ltd.	Azetidinecarboxylic acid derivative and medicinal use thereof
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US20070032522A1 (en)	2005-07-01	2007-02-08	Kumar Dange V	Antiviral agents
US20090306035A1 (en)	2005-08-26	2009-12-10	Emory University	Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest
JO3598B1 (ar)	2006-10-10	2020-07-05	Infinity Discovery Inc	الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP2009023986A (ja)	2006-11-08	2009-02-05	Pharma Ip	抗癌剤としてのビアリール誘導体
CL2008000191A1 (es)	2007-01-25	2008-08-22	Astrazeneca Ab	Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
US9370508B2 (en)	2007-02-20	2016-06-21	Novartis Ag	Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US7691851B2 (en)	2007-03-07	2010-04-06	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
US8039505B2 (en)	2007-04-11	2011-10-18	University Of Utah Research Foundation	Compounds for modulating T-cells
PE20090717A1 (es)	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9321730B2 (en)	2007-08-21	2016-04-26	The Hong Kong Polytechnic University	Method of making and administering quinoline derivatives as anti-cancer agents
CA2925257C (en)	2008-03-26	2019-04-30	Carlos Garcia-Echeverria	5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
PE20110570A1 (es)	2008-07-01	2011-08-26	Genentech Inc	Heterociclos biciclicos sustituidos
WO2010007756A1 (ja)	2008-07-14	2010-01-21	塩野義製薬株式会社	Ｔｔｋ阻害作用を有するピリジン誘導体
EP2356120B1 (en)	2008-09-30	2016-10-12	Pfizer Inc.	Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
WO2010077680A2 (en)	2008-12-08	2010-07-08	Vm Discovery Inc.	Compositions of protein receptor tyrosine kinase inhibitors
WO2010114919A2 (en)	2009-04-02	2010-10-07	Stc.Unm	Metnase and intnase inhibitors and their use in treating cancer
TW201041888A (en)	2009-05-06	2010-12-01	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
JP2012528829A (ja) *	2009-06-04	2012-11-15	ノバルティスアーゲー	１Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
WO2010139731A1 (en) *	2009-06-04	2010-12-09	Novartis Ag	1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
RU2557658C2 (ru)	2009-09-28	2015-07-27	Ф.Хоффманн-Ля Рош Аг	Бензоксепиновые ингибиторы pi3 и способы применения
GB0919423D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
CN102199152A (zh)	2010-03-25	2011-09-28	高大新	杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) *	2010-08-18	2014-09-17	山东轩竹医药科技有限公司	咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012025213A2 (en)	2010-08-23	2012-03-01	Grünenthal GmbH	Novel therapeutic compounds
DE102010035744A1 (de)	2010-08-28	2012-03-01	Merck Patent Gmbh	Imidazolonylchinoline
CN102399218A (zh)	2010-09-16	2012-04-04	和记黄埔医药（上海）有限公司	一类并合三杂环及其作为pi3k抑制剂的用途
AR083267A1 (es)	2010-10-04	2013-02-13	Novartis Ag	Combinaciones farmaceuticas
EP2645999A2 (en)	2010-12-03	2013-10-09	Novartis AG	Pharmaceutical compositions
BR112013013837A2 (pt)	2010-12-06	2016-09-13	Piramal Entpr Ltd	derivados de substituição de imidazoquinolina
WO2012083866A1 (en)	2010-12-22	2012-06-28	The Hong Kong Polytechnic University	Quinoline derivatives as anti-cancer agents
WO2012092471A2 (en)	2010-12-29	2012-07-05	Development Center For Biotechnology	Novel tubulin inhibitors and methods of using the same
JO3003B1 (ar) *	2011-01-14	2016-09-05	Lilly Co Eli	مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
EP2694678A2 (en)	2011-04-04	2014-02-12	Netherland Cancer Institute	Methods and compositions for predicting resistance to anticancer treatment
WO2012162254A1 (en)	2011-05-23	2012-11-29	Elan Pharmaceuticals, Inc.	Inhibitors of lrrk2 kinase activity
US10533000B2 (en)	2011-05-26	2020-01-14	Sunovion Pharmaceuticals, Inc.	Metabotrophic glutamate receptor 5 modulators and methods of use thereof
WO2013022740A2 (en)	2011-08-05	2013-02-14	Corning Incorporated	Gpr35 ligands and the uses thereof
JP6042060B2 (ja)	2011-09-26	2016-12-14	サノフイ	ピラゾロキノリノン誘導体、その調製および治療上の使用
JP6041886B2 (ja)	2011-11-07	2016-12-14	スノヴィオンファーマシューティカルズインコーポレイテッドＳｕｎｏｖｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	オピオイド受容体の調節物質およびそれを含む薬学的組成物
WO2013074965A1 (en)	2011-11-16	2013-05-23	Microbiotix, Inc.	Aminoalkyl phenol ether inhibitors of influenza a virus
WO2013157018A1 (en)	2012-04-18	2013-10-24	Indian Institute Of Technology Madras	A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics
BR112014030099A2 (pt)	2012-06-06	2017-06-27	Novartis Ag	combinação de um inibidor 17-alfa-hidroxilase(c17,20-liase) e um inibidor pi-3 k específico para tratamento de uma doença de tumor
WO2013184755A2 (en)	2012-06-07	2013-12-12	Georgia State University Research Foundation, Inc.	Seca inhibitors and methods of making and using thereof
WO2013192367A1 (en)	2012-06-22	2013-12-27	Novartis Ag	Neuroendocrine tumor treatment
IN2015DN00528A (lt)	2012-08-16	2015-06-26	Novartis Ag
WO2014031872A2 (en)	2012-08-23	2014-02-27	The Broad Institute, Inc.	Small molecule inhibitors for treating parasitic infections
CN105142641A (zh)	2013-03-12	2015-12-09	广州源生医药科技有限公司	用于治疗癌症的化合物
GB201309180D0 (en)	2013-05-21	2013-07-03	Ucl Business Plc	Compounds and Their Uses
WO2015073804A2 (en)	2013-11-15	2015-05-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Method of blocking transmission of malarial parasite
JP2016540773A (ja) *	2013-12-06	2016-12-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用な化合物
NO2714752T3 (lt) *	2014-05-08	2018-04-21
GB201409044D0 (en)	2014-05-21	2014-07-02	Ucl Business Plc	New compounds
EP3277681B1 (de)	2015-04-02	2019-05-08	Merck Patent GmbH	Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
CN104876912B (zh)	2015-04-08	2017-07-21	苏州云轩医药科技有限公司	Wnt信号通路抑制剂及其应用
WO2017011323A1 (en)	2015-07-10	2017-01-19	University Of Maryland, Baltimore	Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
GB201516504D0 (en) *	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
BR112018068703B1 (pt)	2016-03-16	2024-02-06	Kura Oncology, Inc.	Inibidores substituídos de menin-mll e métodos de uso

2015
- 2015-09-17 GB GBGB1516504.6A patent/GB201516504D0/en not_active Ceased
2016
- 2016-09-14 TW TW109145998A patent/TWI762109B/zh active
- 2016-09-14 TW TW105129931A patent/TWI714631B/zh active
- 2016-09-15 ES ES20156172T patent/ES2920876T3/es active Active
- 2016-09-15 PL PL16770461T patent/PL3350180T3/pl unknown
- 2016-09-15 PE PE2018000343A patent/PE20181078A1/es unknown
- 2016-09-15 HU HUE20156172A patent/HUE058884T2/hu unknown
- 2016-09-15 CN CN201680052951.0A patent/CN108137576B/zh active Active
- 2016-09-15 WO PCT/EP2016/071782 patent/WO2017046216A1/en not_active Ceased
- 2016-09-15 HR HRP20210149TT patent/HRP20210149T1/hr unknown
- 2016-09-15 CA CA2997399A patent/CA2997399C/en active Active
- 2016-09-15 CR CR20180172A patent/CR20180172A/es unknown
- 2016-09-15 JP JP2018513812A patent/JP6605130B2/ja active Active
- 2016-09-15 DK DK20156172.7T patent/DK3683220T3/da active
- 2016-09-15 KR KR1020197028342A patent/KR102469153B1/ko active Active
- 2016-09-15 EP EP20156172.7A patent/EP3683220B1/en active Active
- 2016-09-15 MY MYPI2023000366A patent/MY198813A/en unknown
- 2016-09-15 AU AU2016323399A patent/AU2016323399B2/en active Active
- 2016-09-15 MY MYPI2018701049A patent/MY195669A/en unknown
- 2016-09-15 PL PL20156172.7T patent/PL3683220T3/pl unknown
- 2016-09-15 PT PT167704618T patent/PT3350180T/pt unknown
- 2016-09-15 BR BR112018004325-7A patent/BR112018004325B1/pt active IP Right Grant
- 2016-09-15 RS RS20210170A patent/RS61435B1/sr unknown
- 2016-09-15 PT PT201561727T patent/PT3683220T/pt unknown
- 2016-09-15 DK DK16770461.8T patent/DK3350180T3/da active
- 2016-09-15 SI SI201631074T patent/SI3350180T1/sl unknown
- 2016-09-15 TN TNP/2018/000078A patent/TN2018000078A1/en unknown
- 2016-09-15 LT LTEP16770461.8T patent/LT3350180T/lt unknown
- 2016-09-15 EP EP16770461.8A patent/EP3350180B1/en active Active
- 2016-09-15 HU HUE16770461A patent/HUE053066T2/hu unknown
- 2016-09-15 KR KR1020187010323A patent/KR102028848B1/ko active Active
- 2016-09-15 ES ES16770461T patent/ES2853924T3/es active Active
- 2016-09-15 EA EA201890650A patent/EA033284B1/ru not_active IP Right Cessation
- 2016-09-15 SM SM20210071T patent/SMT202100071T1/it unknown
- 2016-09-15 MX MX2018003186A patent/MX384930B/es unknown
- 2016-09-16 US US15/267,398 patent/US9856255B2/en active Active
- 2016-09-16 AR ARP160102832A patent/AR106053A1/es active IP Right Grant
2017
- 2017-11-27 US US15/822,617 patent/US10457679B2/en active Active
2018
- 2018-02-26 NI NI201800033A patent/NI201800033A/es unknown
- 2018-03-04 IL IL257847A patent/IL257847B/en active IP Right Grant
- 2018-03-06 DO DO2018000065A patent/DOP2018000065A/es unknown
- 2018-03-12 PH PH12018500532A patent/PH12018500532A1/en unknown
- 2018-03-14 CL CL2018000677A patent/CL2018000677A1/es unknown
- 2018-03-16 SV SV2018005655A patent/SV2018005655A/es unknown
- 2018-03-16 CO CONC2018/0002829A patent/CO2018002829A2/es unknown
2019
- 2019-09-27 US US16/584,996 patent/US10882858B2/en active Active
2020
- 2020-12-01 US US17/108,117 patent/US11613539B2/en active Active
2021
- 2021-02-11 CY CY20211100117T patent/CY1124680T1/el unknown
2022
- 2022-08-16 ZA ZA2022/09171A patent/ZA202209171B/en unknown
2023
- 2023-02-21 US US18/171,735 patent/US20230286981A1/en active Pending

Also Published As

Publication number	Publication date
NZ741661A (en)	2024-04-26
CA2997399C (en)	2024-02-20
TWI714631B (zh)	2021-01-01
AU2016323399B2 (en)	2019-04-18
US20200102302A1 (en)	2020-04-02
GB201516504D0 (en)	2015-11-04
ZA202209171B (en)	2023-11-29
EA201890650A1 (ru)	2018-10-31
US20180141943A1 (en)	2018-05-24
JP6605130B2 (ja)	2019-11-13
PT3350180T (pt)	2021-02-08
PE20181078A1 (es)	2018-07-05
PL3683220T3 (pl)	2022-08-01
SV2018005655A (es)	2018-04-27
EP3683220A1 (en)	2020-07-22
MX384930B (es)	2025-03-14
DK3683220T3 (da)	2022-07-04
MX2018003186A (es)	2018-05-17
US11613539B2 (en)	2023-03-28
KR102469153B1 (ko)	2022-11-22
ES2853924T3 (es)	2021-09-20
EP3350180A1 (en)	2018-07-25
MY195669A (en)	2023-02-03
AR106053A1 (es)	2017-12-06
DK3350180T3 (da)	2021-02-15
IL257847B (en)	2020-08-31
TWI762109B (zh)	2022-04-21
KR102028848B1 (ko)	2019-10-04
CO2018002829A2 (es)	2018-05-31
US20210147416A1 (en)	2021-05-20
US20230286981A1 (en)	2023-09-14
MY198813A (en)	2023-09-29
NI201800033A (es)	2018-10-18
EA033284B1 (ru)	2019-09-30
US10457679B2 (en)	2019-10-29
CL2018000677A1 (es)	2018-08-17
WO2017046216A1 (en)	2017-03-23
HUE053066T2 (hu)	2021-06-28
US20170081325A1 (en)	2017-03-23
SI3350180T1 (sl)	2021-03-31
KR20190112852A (ko)	2019-10-07
US9856255B2 (en)	2018-01-02
CN108137576B (zh)	2020-09-22
IL257847A (en)	2018-04-30
BR112018004325B1 (pt)	2023-10-17
RS61435B1 (sr)	2021-03-31
JP2018531226A (ja)	2018-10-25
AU2016323399A1 (en)	2018-05-10
TW201722946A (zh)	2017-07-01
TN2018000078A1 (en)	2019-07-08
BR112018004325A2 (lt)	2018-10-02
PH12018500532A1 (en)	2018-08-29
HUE058884T2 (hu)	2022-09-28
HK1255408A1 (zh)	2019-08-16
CN108137576A (zh)	2018-06-08
CY1124680T1 (el)	2022-07-22
DOP2018000065A (es)	2018-03-30
PT3683220T (pt)	2022-06-24
TW202124381A (zh)	2021-07-01
CR20180172A (es)	2018-05-25
US10882858B2 (en)	2021-01-05
HK1257413A1 (en)	2019-10-18
HRP20210149T1 (hr)	2021-03-19
PL3350180T3 (pl)	2021-05-17
KR20180052724A (ko)	2018-05-18
ES2920876T3 (es)	2022-08-11
SMT202100071T1 (it)	2021-03-15
CA2997399A1 (en)	2017-03-23
EP3350180B1 (en)	2020-11-11
EP3683220B1 (en)	2022-04-13

Publication	Publication Date	Title
LT3350180T (lt)	2021-02-25	8-[6-[3-(amino)propoksi]-3-piridil]-1-iizopropil-imidazo[4,5-c]chinolin-2-ono dariniai, kaip selektyvūs ataksijos-telangiektazijos mutuotos (atm) kinazės moduliatoriai, skirti vėžio gydymui
HRP20210518T1 (hr)	2021-05-14	Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
LT3523301T (lt)	2020-07-27	Pakeistieji pirazolo[1,5-a]piridino junginiai kaip ret kinazės slopikliai
DK3355884T3 (da)	2021-08-02	Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
IL255433A (en)	2018-02-28	(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
LT3468965T (lt)	2020-06-10	1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indolo junginiai vėžio gydymui
IL242170B (en)	2020-08-31	Derivatives of 3-(2-aminopyrimidine-4yl)-5-(3-hydroxypropynyl)-h1-pyrrolo[2,3-pyridine as nickel inhibitors for cancer treatment
LT3390390T (lt)	2021-11-25	Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
HUE051448T2 (hu)	2021-03-01	Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
HUE055463T2 (hu)	2021-11-29	Eljárás glükopiranozil-szubsztituált benzil-benzol-származékok elõállítására
LT3377094T (lt)	2021-08-10	Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
DK3452465T3 (da)	2021-02-08	Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
LT3386997T (lt)	2021-12-10	Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
ZA201808014B (en)	2020-02-26	Adenine derivatives as protein kinase inhibitors
LT3113778T (lt)	2018-08-27	Piridazino dariniai, skirti naudoti ataksinio sutrikimo profilaktikai arba gydymui
HUE053358T2 (hu)	2021-06-28	5-Metil-6-fenil-4,5-dihidro-2H-piridazin-3-on származék agytumorok kezelésére
LT3500572T (lt)	2023-02-10	Citizino dariniai, skirti priklausomybių gydymui
LT3290436T (lt)	2019-10-10	Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui
LT3244889T (lt)	2020-08-10	Farmacinė kompozicija, skirta mikozės gydymui
TH1601000114A (th)	2017-10-12	อนุพันธ์ไทอีโน [3,2-d] ไพริมิดีน สำหรับการบำบัดการติดเชื้อไวรัส
TH1501000894A (th)	2016-11-29	อนุพันธ์ไดอะซีพิโนนที่เป็นประโยชน์สำหรับการรักษาของกลุ่มอาการ โครโมโซมเอกซ์เปราะบาง, พาร์กินสันส์หรือโรคกรดไหลย้อน